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Abstract
DNMT3A mutations are observed in myeloid malignancies, including myeloproliferative 
neoplasms (MPN), myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). 
Transplantation studies have elucidated an important role for Dnmt3a in stem cell self-renewal and 
in myeloid differentiation. Here we investigated the impact of conditional hematopoietic Dnmt3a 
loss on disease phenotype in primary mice. Mx1-Cre-mediated Dnmt3a ablation led to the 
development of a lethal, fully penetrant myeloproliferative neoplasm with myelodysplasia (MDS/
MPN) characterized by peripheral cytopenias and by marked, progressive hepatomegaly. We 
detected expanded stem/progenitor populations in the liver of Dnmt3a-ablated mice. The 
MDS/MPN induced by Dnmt3a ablation was transplantable, including the marked hepatomegaly. 
Homing studies showed that Dnmt3a-deleted bone marrow cells preferentially migrated to the 
liver. Gene expression and DNA methylation analyses of progenitor cell populations identified 
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differential regulation of hematopoietic regulatory pathways, including fetal liver hematopoiesis 
transcriptional programs. These data demonstrate that Dnmt3a ablation in the hematopoietic 
system leads to myeloid transformation in vivo, with cell autonomous aberrant tissue tropism and 
marked extramedullary hematopoiesis (EMH) with liver involvement. Hence, in addition to the 
established role of Dnmt3a in regulating self-renewal, Dnmt3a regulates tissue tropism and limits 
myeloid progenitor expansion in vivo.
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Introduction
Aberrant epigenetic patterning is a cornerstone of the molecular pathogenesis of cancers, 
including myeloid malignancies1. DNMT3A (DNA methyltransferase 3A) mutations are 
detected in 8–10% of myeloproliferative neoplasms (MPN) and myelodysplastic syndromes 
(MDS)2–4, and in 20–25% of acute myeloid leukemias (AML)5–8. These mutations occur as 
monoallelic or biallelic nonsense/frameshift alterations, or a dominant-negative R882 
substitution9, 10. DNMT3A-mutant AMLs exhibit global and site-specific alterations in 
DNA methylation10, also observed in chronic myelomonocytic leukemia (CMML) patients 
with DNMT3A mutations11.
Although these data underscore the importance of DNMT3A mutations to myeloid 
transformation, the specific mechanisms by which DNMT3A functions as a tumor 
suppressor have not been fully elucidated. It is possible that mutations in epigenetic modifier 
genes alter the epigenetic state of normal hematopoietic stem/progenitor cells (HSPC), 
which allows malignant cells to re-access earlier developmental transcriptional programs. 
Notably, such features as enhanced hematopoietic stem cell self-renewal, increased 
proliferative capacity, myeloid bias, and extramedullary hematopoiesis (EMH), are shared 
between fetal liver hematopoiesis and MDS/MPN12, 13.
Previous studies on Dnmt3a loss in adult hematopoiesis used transplantation assays to 
document expansion of the stem/progenitor compartment, most prominently long-term 
HSCs, a gain in self-renewal, and a decline in the output of differentiated progeny14. 
Moreover, a subset of recipients developed different hematologic malignancies15, 16. 
However, these studies did not assess the tumor suppressor function of Dnmt3a in the 
absence of the selective pressure of serial transplantation, or whether Dnmt3a loss is 
sufficient to induce transformation in vivo. We therefore characterized the impact of 
conditional Dnmt3a loss in the hematopoietic compartment to assess impact on disease 
phenotype in vivo, and on steady-state adult hematopoiesis, coupled with studies of the 
effect of Dnmt3a loss on DNA methylation and transcriptional state.
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Materials and Methods
Animal studies
were approved by the Institutional Animal Care and Use Committee of Memorial Sloan 
Kettering Cancer Center. Dnmt3af/f conditional knock-out (cKO) line17 was reconstituted 
from frozen embryos (The Jackson Laboratory, Bar Harbor, ME), backcrossed to C57BL/6 
background, and crossed to Mx1-Cre-deletor line. See supplemental methods.
Colony-forming assay in semisolid media
was performed using previously published method18 with modifications. See supplemental 
methods.
Homing assay
was performed as described19 with modifications. See also supplemental methods.
Gene expression and DNA methylation analyses
were performed on FACS-sorted LSK and GMP cells. Enhanced Reduced Representation of 
Bisulfite Sequencing (ERRBS) was used to determine cytosine methylation patterns at base 
pair resolution20, 21. RNA was subjected to standard Illumina-based sequencing. For detailed 
description see supplemental methods.
Statistical analysis
Except where indicated, data are presented as mean ± standard deviation plotted using Prism 
version 6 (GraphPad Software). Statistical significance was determined using Student’s t-test 
with Holm-Sidak correction method, with α=5.0%.
Results
Hematopoietic-specific inactivation of Dnmt3a results in lethal hematologic disease
We first investigated the role of Dnmt3a in steady-state hematopoiesis. Mx1-Cre-driven 
recombination results in complete loss of Dnmt3a protein in the hematopoietic system 
(Figures 1A and S1A) and leads to a lethal, fully penetrant disease (median survival 48.6 
weeks, p<0.0001, Figure 1B). None of the Dnmt3a+/+:Mx1-Cre+ or Dnmt3af/f:Mx1-Cre− 
animals developed hematologic abnormalities within a 90-week follow-up period. Dnmt3a-
ablated mice developed progressive macrocytic anemia with anisocytosis, 
thrombocytopenia, and monocytosis (Figures 1C–H and S1B–G). Examination of the 
hematocrit and platelet counts over time revealed progressive anemia and thrombocytopenia 
(Figure 1I–J).
Dnmt3a loss induces mature myeloid and myeloid progenitor expansion in vivo
Detailed analysis of the hematopoietic system in Dnmt3a KO mice found marked myeloid 
bias and myeloid and erythroid dysplasia in peripheral blood (Figures 2A–B) accompanied 
by hypercellular bone marrow (Figure S2A) with megakaryocyte dysplasia (Figure 2C). We 
found increased spleen size (Figures 2D) and effacement of splenic architecture by myeloid 
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infiltration, and scattered dysplastic megakaryocytes (Figure 2E), consistent with 
myeloproliferation, confirmed by flow cytometry (Figures 2F and S2B). We observed an 
increase in the stem-cell-enriched Lineage−Sca-1+c-Kit+ (LSK) and in Lineage−Sca-1−c-
Kit+ (LK) myeloid progenitor cells, with significant expansion of GMPs (Figure 2G–H). The 
findings of hypercellular bone marrow with dysplasia, myeloid bias in the peripheral blood, 
and extramedullary hematopoiesis is consistent with a myeloproliferative/myelodysplastic 
disorder (MDS/MPN).
Impaired erythroid maturation after Dnmt3a loss
To gain insight into the mechanism of anemia in diseased Dnmt3a-null mice we examined 
erythroid maturation in bone marrow and spleens according to CD71 and Ter119 
markers22, 23 and found a decrease in the mature stage IV erythroblasts and an increase in 
stage II CD71+Ter119+ cells, most pronounced in the spleens, without significant changes in 
apoptosis (Figure S2C–E), consistent with a previous report15. We also observed 
erythrophagocytosis in the spleens and livers of Dnmt3a-deleted animals (Figure S2F).
Perturbation of the stem/progenitor compartment and increased self-renewal of Dnmt3a 
deficient hematopoietic cells
Previous studies found increased numbers of primitive HSCs, but not of immediate 
downstream progenitors, in recipient mice reconstituted with Dnmt3a-ablated HSCs14. In 
this setting the impact of stress from bone marrow transplantation could not be 
unequivocally separated from the cell-intrinsic HSC phenotype. Detailed analysis of HSPCs 
in diseased primary Dnmt3a KO animals showed a significant increase in the relative 
frequency of the immature LSK population. This expansion was due to elevated LSK CD48+ 
cells while the LSK CD48−CD150+ LT-HSC population remained unperturbed, and we 
observed an increase in committed myeloid progenitors (Figures 3A–B and S3A). Overall, 
Dnmt3a-deficient HSPCs were characterized by increased proliferation and decreased 
apoptosis (Figure 3C–D). The increased frequency of CD48+ LSK cells accompanied by 
predominant myelopoiesis relative to lymphopoiesis, and increased self-renewal and multi-
lineage reconstitution potential are characteristic of fetal hematopoiesis13. We observed a 
prominent cKit+CD41+ population in the bone marrow of Dnmt3a-deleted mice, which is 
nearly absent in normal adult hematopoiesis (Figure S2G).
To assess the self-renewal potential of bone marrow cells we performed colony-forming 
assays. Dnmt3a loss resulted in continuous serial replating, while control cells rapidly 
exhausted their colony-forming ability (Figure 3E). In serial competitive transplantation 
assays in vivo Dnmt3a KO cells showed robust repopulation advantage compared to wild-
type control (Figure S3B–C), which was more pronounced in the bone marrow 
compartment, and continued to increase with each round of transplantation (Figure 3F–G). 
These observations suggest that loss of Dnmt3a augments stem cell function in vitro and in 
vivo.
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Dnmt3a loss results in hepatomegaly due to liver-specific myeloproliferation and 
extramedullary hematopoiesis
All moribund Dnmt3a-deleted animals presented with distended abdomens and marked 
hepatomegaly (Figure 4A–B). Histopathologically Dnmt3a KO livers showed portal, lobular, 
sinusoidal infiltration by immature myeloid cells with open chromatin and prominent 
nucleoli, scattered megakaryocytes, and occasional blasts (Figure 4C), confirmed by FACS 
analysis that also showed prominent monocytosis (Figure 4D–E and S4A). Alkaline 
phosphatase (ALP) and bilirubin levels were elevated and albumin levels decreased (Figures 
4F and S4B), consistent with impaired liver function.
Histological detection of megakaryocytes in infiltrated liver parenchyma after Dnmt3a 
inactivation suggested that liver was a site of hematopoiesis. Analysis of HSPCs residing in 
the liver detected myeloid progenitor LK and stem-cell-enriched LSK cells in Dnmt3a-null 
mice, but not in wild-type animals (Figure S4C). Plating of Dnmt3a KO liver cells yielded 
colonies with characteristic granulocyte-erythroid-macrophage-megakaryocyte (GEMM) 
and granulocyte-macrophage (GM) morphology that serially replated (Figure 4G) similar to 
continuously self-renewing Dnmt3a-ablated bone marrow cells. By contrast, cells derived 
from wild-type control livers were unable to give rise to hematopoietic colonies in vitro.
Dnmt3a-deleted bone marrow cells exhibit cell-intrinsic liver tropism
As Mx1-Cre is able to mediate excision, in addition to HSCs, in hepatic and perivascular 
cells24, 25, we examined if extramedullary tropism of Dnmt3a KO hematopoietic cells was 
due to cell-intrinsic or niche-dependent mechanism by performing short-term homing 
studies (Figure 5A). While the ability of Dntm3a-deficient cells to home to the bone marrow 
was unaltered, they showed preferential liver tropism (Figure 5B–C). Interestingly, CD45+ 
Dnmt3a KO liver cells exhibited even stronger hepatotropism than bone marrow cells from 
the same animals (Figure S5A). These findings demonstrate that preferential liver homing of 
Dnmt3a-null hematopoietic cells is mediated by a cell-intrinsic mechanism.
Hematopoietic-specific Dnmt3a loss results in cell-autonomous myeloproliferation and 
liver-specific myeloid expansion in secondary recipients
We tested the ability of Dnmt3a-deficient hematopoietic cells to re-initiate MDS/MPN by 
transplantation into sublethally-irradiated congenic hosts. No engraftment was observed 12 
weeks post-transplant confirming that the hematologic disease represents MDS/MPN, and 
not AML. Conversely, transplantation into lethally-irradiated recipients resulted in a fully 
penetrant, rapidly fatal disease with a median latency of 13.4 weeks (Figure 5D, p<0.0001) 
that recapitulated the MDS/MPN seen in primary mice with hepatosplenomegaly (Figure 5E 
and S5B). Similar results were obtained when recipient mice were transplanted with CD45+ 
cells isolated from Dnmt3a-deleted livers, suggesting that disease-initiating cells are present 
in the liver (data not shown). Dnmt3a KO-transplanted livers showed myeloid infiltration 
and histiocytic hyperplasia (Figure 5F). Recipient mice developed thrombocytopenia, 
decreased hematocrit and peripheral blood leukocytosis with monocytosis (Figures 5G–H 
and S5C–D). In contrast to primary Dnmt3a KO mice, transplant recipients showed both 
myeloid and T-lymphoid bias, and bi-lineage expansion (Figure S5E–F).
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Extramedullary hematopoiesis in MDS/MPN patients with DNMT3A mutations
To extend our studies to the human context we examined whether DNMT3A mutations are 
associated with EMH in a well-annotated cohort of 46 patients with the MDS/MPN overlap 
syndrome CMML11. DNMT3A-mutant patients had a higher rate of clinically evident EMH 
(Figure 5I): 2 of 4 DNMT3A-mutant patients (50%) presented with hepatosplenomegaly and 
lymphadenopathy due to extramedullary CMML, while only 7.14% (3/42) DNMT3A-WT 
patients showed similar extramedullary involvement (p=0.053 and Phi=+0.39, 2-tailed 
Fisher’s exact test). These data underscore the tumor suppressor role of Dnmt3a and 
association of DNMT3A loss with EMH in the clinical context.
DNA methylation profiling reveals decreased methylation upon Dnmt3a loss at loci with 
regulatory potential
To assess whether the Dnmt3a KO phenotype was linked to aberrant epigenetic 
programming we analyzed DNA methylation patterns in LSK and GMP cells. Enhanced 
reduced-representation bisulfite sequencing (ERRBS) followed by unsupervised hierarchical 
clustering of genome-wide cytosine methylation profiles showed segregation of Dnmt3a 
wild-type and mutant samples (Figure S6A). Genome-wide CpG methylation values 
revealed regions of marked DNA demethylation upon Dnmt3a loss (Figure 6A; p<0.01, 
Wilcoxon two-tailed rank sum test). Of the 822 differentially methylated regions in GMPs 
(DMRs - methylKit: q<0.01 and ≥20% methylation difference; methylSig: beta-binomial 
p≤0.25 and methylation difference ≥10%; Table S1) 797 (97%) were hypomethylated in 
Dnmt3a-ablated mice (Figure S6B) with particular enrichment for hypomethylated CpGs 
within introns, gene neighborhoods, and intergenic regions (p<0.01, 1-tailed Fisher’s exact 
test; Figure 6B). We next focused our analyses on GMPs as we observed a marked increase 
in the proportion of GMPs in vivo. A trend toward hypomethylation was seen at gene 
promoters (Figures 6B and S6C). Overall, GMP-stage active enhancers showed a greater 
degree of methylation loss than promoters, exons, introns, gene neighborhoods, or intergenic 
regions (p<0.01, Wilcoxon one-tailed rank-sum test with continuity correction; Figure 6C). 
A subset of genes associated with hypomethylated DMRs had increased expression by the 
RNA-sequencing analysis (Figure S6E). Furthermore, in GMPs significantly 
hypomethylated regions were enriched in binding sites with homology to Ets family 
transcription factor Elk4, zinc finger and BTB domain containing transcription factor Zbtb3, 
and Forkhead class transcription factor FoxP1, implicated as tumor suppressors, while 
HoxA9 was among notable findings in LSKs (Figure S6D)26–28. Gene ontology analysis by 
biological process applied to DMCs within gene promoters revealed significant enrichment 
of genes involved in cell adhesion (CD97, Icam2, Ppard, Cldn4, Eng, Ninj2, protocadherins 
and cadherin-related protein genes), regulation of RNA polymerase II-driven transcription 
(Srebf1, FoxH1, HoxB1, Cebpb, Hand1, Nr4a2, Tead2, Jak3), and embryonic development 
(HoxB1, Cebpb, Hand1, Hlx, HoxA6, HoxB6; Figure 6E). These data suggest that the 
hypomethylation observed with Dnmt3a loss may have a functional role in regulating 
transcriptional gene states.
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Gene expression profiling identifies reprogramming towards a more primitive 
developmental state with Dnmt3a loss
RNA-sequencing identified 218 upregulated and 98 downregulated genes in Dnmt3a-null 
GMPs (Figure 6D; adjusted p<0.1), including genes implicated in embryonic and cancer 
stem cell phenotypes cMyc29, Lifr30, Bmx31, Satb132, positive and negative regulators of 
tumor invasion Adam3, Ptk733, serpin34 and semaphorin35 family proteins and ephrin 
receptor ligands, and networks associated with hematopoietic cell lineage, cell surface 
receptors, and regulation of immune systems (Figures 6F and S6F, Table S2). Among 
hypomethylated genes that showed corresponding expression changes, in addition to Adam3 
and Ptk7, were Svep1, Hivep2, Lrp1, Cds1, Padi1, Zfp618 that regulate cell attachment and 
amplify cellular signaling responses from cytokines. Gene set enrichment analysis (GSEA) 
found enrichment of HSC signature genes36 in Dnmt3a-null GMPs consistent with enhanced 
self-renewal. Comparison with the fetal hematopoiesis gene expression signature37 (Figure 
6G) along with positive enrichment for PRC2-regulated genes and negative enrichment for 
the ES cell differentiation genes confirmed transcriptional reactivation of early 
developmental programs after Dnmt3a loss. In line with previous reports6, 38 we found 
increased expression of Hox genes and of their targets in Dnmt3a-null GMPs (Figure S6G–
H). Increased expression of the cell adhesion molecules is consistent with hypomethylation 
within their promoters and altered cell tropism of the Dnmt3a-ablated bone marrow cells 
(Figures 6E and S6H). These data indicate that key regulator genes and gene networks are 
transcriptionally modified by Dnmt3a loss.
Discussion
Our findings emphasize the crucial role of Dnmt3a in the pathogenesis of hematologic 
malignancies, by showing Dnmt3a in primary mice gives rise to a fully penetrant, lethal 
myeloid disease. Although studies of Dnmt3a-deficient hematopoiesis in adoptive transfer 
experiments has produced invaluable insights14–16, the variable impact on disease phenotype 
may be due to the selective pressure of transplantation, which has been suggested to be 
necessary to unmask the malignant transformation induced in Dnmt3a-deficient HSCs15. 
Our data provide an unequivocal role for Dnmt3a in inducing myeloid transformation in 
primary mice in the absence of transplantation. Our studies and previous studies relied on 
interferon-activated Mx1-Cre excision14–16 which may force HSCs to enter cell cycle39, 40. 
Hence an inflammatory component may be an important contributing factor into the 
pathogenesis of hematopoietic failure syndromes, consistent with clinical observations41. 
Dnmt3a loss resulted in expansion of the immature compartment in the bone marrow, 
including LSK and GMP cells, concomitant with pronounced monocytosis. This pattern of 
quantitative changes reveals compromised differentiation at several stages, paralleling high-
risk subtypes of MDS and a disproportionate association of DNMT3A-mutations with 
monocytic disease observed in the clinic42, 43. These findings reinforce the clinical relevance 
of Dnmt3a-deficient hematopoiesis as a faithful animal model of human disease, including 
MDS/MPN.
Dnmt3a-deficient hematopoiesis shares similarities with HSC expansion within the fetal 
liver, including expansion of CD48+ LSK ST-HSCs and MPPs and lower relative 
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frequencies of CD150+CD48− LSK LT-HSCs, preferential myelopoiesis with lower Gr-1 
expression, and changes in erythroid maturation, including a prominent CD41+ cKit+ 
population not found in adult hematopoiesis. Most importantly, deletion of functional 
Dnmt3a leads to robust gain in self-renewal and long-term multilineage reconstituting 
potential, which is a hallmark of fetal hematopoiesis13, 37, 44, 45. We observed enrichment of 
the HSC and fetal liver gene expression signatures in Dnmt3a-null GMPs, along with 
upregulation of embryonic and cancer stem cell-associated genes. It is tempting to speculate 
that these phenotypic changes arise due to partial reprogramming towards developmentally 
more primitive state by impaired epigenetic control following Dnmt3a loss. Further studies 
examining expression of fetal stem/progenitor markers and transcriptomic switches will be 
necessary to address the potential role of Dnmt3a function in hematopoietic development.
The most striking finding in Dnmt3a-deleted myeloproliferation/myelodysplasia is the 
hepatomegaly due to EMH and liver-specific myeloproliferation. The ability of adult 
hematopoietic cells to home, colonize, and mature in the liver reflects primitive 
developmental patterns of hematopoiesis and re-establishment of a stem cell niche46. 
Reminiscent of fetal hematopoiesis, hepatic EMH in Dnmt3a-null animals was 
predominantly localized within sinusoids. The mechanism of homing to the liver is distinct 
from other organs, as the lower blood flow and fenestrated endothelium in the sinusoids do 
not require selectin-mediated rolling for leukocyte recruitment, suggesting other adhesion 
mechanisms play a prominent role47. Gene expression analysis of Dnmt3a-deleted GMPs 
identified enrichment of a cell adhesion signature that may account for the enhanced liver 
tropism. At the same time, elevated expression of the extracellular matrix degradation and 
tissue invasion genes may contribute to cell mobilization from the bone marrow to the 
liver48, 49, facilitated through epigenetic changes after Dnmt3a loss targeting genomic loci 
with regulatory potential, including Ets binding sites50. These observations may have 
important implications for the treatment of DNMT3A-mutated MDS in humans as EMH in 
the liver may serve as a safe heaven environment and a reservoir for the disease-initiating 
clone. Future interrogation of the specific cell adhesion determinants will help clarify 
molecular mechanisms of hepatotropism of Dnmt3a-ablated hematopoietic cells.
Taken together, Dnmt3a inactivation in primary animals leads to the development of a 
myeloid malignancy with features of human MDS/MPN, highlighting the relevance of this 
model to chronic myeloid neoplasms. We speculate that increased epigenetic plasticity 
allows reactivation of developmental gene expression programs. Subsequent studies are 
needed to explore the role for concomitant disease alleles, and to determine if therapies can 
be developed to prevent and/or reverse the myeloid transformation induced by Dnmt3a loss.
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Figure 1. Primary Dnmt3a conditional knock-out mice have decreased survival and develop 
peripheral blood cytopenias
A. Dnmt3a protein levels after excision in the spleens of Dnmt3af/f:Mx1-Cre+ and control 
mice.
B. Survival of Dnmt3a KO (n=15) and control (n=18) mice. Cre-mediated excision was 
induced by poly(I:C) injections (please see Supplementary Methods). Animals sacrificed as 
controls for diseased Dnmt3a KO mice were censored. Reasons for euthanasia in 2 control 
animals were rectal prolapse and severe bite wounds due to fighting; cause of death in 1 
mouse was undetermined. None of the control mice exhibited signs of hematologic disease.
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C. White blood cell counts at disease onset in Dnmt3a-ablated mice (n=6–7).
D–H. Dnmt3a-deleted mice develop macrocytic anemia (n=6–7) with decreased hematocrit 
(D) and hemoglobin levels (E), increased mean corpuscular volume (F), thrombocytopenia 
(G), and anisocytosis (H) (**, p<0.01; ***, p<0.001).
I–J. Hematocrit (I) and platelet counts (J) over time in 6 Dnmt3a KO and 2 representative 
control mice.
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Figure 2. Dnmt3a-deleted mice develop myelodysplasia/myeloproliferation with extramedullary 
hematopoiesis
A. Myeloid bias in peripheral blood of Dnmt3a-null mice (n=7–8; ***, p<0.001).
B. Peripheral blood smears and bone marrow cytospin preparations showing dysplasia of 
myeloid and erythroid lineages in Dnmt3a-null but not control mice, manifesting as nuclear 
hyposegmentation reminiscent of pseudo-Pelger-Huet neutrophils classically noted in human 
MDS and nucleated red blood cells (arrows) with dyserythropoiesis characterized by 
irregular nuclear contours. Bar – 10 µm.
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C. Representative H/E-stained sections of control and Dnmt3a KO sterna. Arrows – 
megakaryocyte dysplasia. Bar – 50 µm.
D. Spleens weights in Dnmt3a KO and control mice at disease onset (n=6–9; *, p<0.05).
E. Gross pathology and H/E-stained sections of representative control and Dnmt3a-null 
spleens. Arrows – megakaryocytic infiltration. Bar – 1000 µm (low magnification), and 50 
µm (high magnification).
F. Quantification of the CD11b+ cells shows elevated levels of myeloid cells in spleens of 
Dnmt3a-deleted mice at time of disease onset (n=5–6; *, p<0.05).
G. Representative FACS plots of immature stem and progenitor cells in the spleens of 
Dnmt3a-ablated and control mice.
H. Quantification of data presented in G (n=4–6; *, p<0.05; **, p<0.01; ***, p<0.001).
Guryanova et al. Page 15
Leukemia. Author manuscript; available in PMC 2016 June 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. Conditional deletion of Dnmt3a results in perturbation of the hematopoietic stem and 
progenitor compartment and gain of self-renewal potential
A. Relative stem and progenitor cell frequencies in Dnmt3a KO and control bone marrow at 
disease onset (n=4–6; #, p=0.065; *, p<0.05; **, p<0.01).
B. Representative FACS plots for data in A.
C–D. Increased proliferation and decreased quiescence (C) and decreased apoptosis (D) in 
Dnmt3a-deleted compared to wild-type HSPCs in animals competitively transplanted with 
bone marrow cells derived from Dnmt3a-null (CD45.2) and wild-type (CD45.1) mice. 
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Analysis was performed in 4 transplant recipients 9 months after transplantation (*, p<0.05; 
**, p<0.01).
E. CFU assay on bone marrow cells from Dnmt3a-null or control littermates. Representative 
results of 3 independent experiments, each performed in triplicate.
F. CD45.1/CD45.2 chimerism in bone marrow LSK cells over three rounds of serial 
competitive transplantation. Test cells (CD45.2, red bars – Dnmt3a KO, black bars – WT) 
were competed against wild-type (CD45.1, white bars) and analyzed 16 weeks after 
transplantation (n=5; ***, p<0.001). Dotted line represents CD45.1/CD45.2 cell ratio at time 
of injection (50%).
G. CD45.1/CD45.2 peripheral blood chimerism in tertiary recipients 16 weeks after 
transplantation in D. Representative FACS plots.
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Figure 4. Hepatomegaly due to myeloproliferation and monocytic infiltration in conditional 
Dnmt3a knock-out mice
A. Gross pathology of livers and overall appearance of control and diseased Dnmt3a-deleted 
mice, representative of all animals studied.
B. Liver weights in Dnmt3a-KO and WT mice at disease onset (n=7–10; *** p<0.001).
C. H/E-stained liver sections; arrows – scattered megakaryocytes in Dnmt3a-ablated but not 
control mice. Bar – 50 µm.
D. Quantification of CD11b+ cells in livers of control and diseased Dnmt3a KO mice (n=3–
6; **, p<0.01).
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E. Representative FACS plots for data presented in (D).
F. Serum alkaline phosphatase (ALP) and bilirubin levels in control and diseased Dnmt3a-
deleted mice (n=4–7; *, p<0.05; **, p<0.01).
G. Colony-forming assay using liver cells from diseased Dnmt3a knock-out mouse, single 
experiment performed in triplicate.
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Figure 5. Conditional loss of Dnmt3a results in cell-autonomous liver tropism
A. Schematic depiction of the homing assay workflow.
B. Relative homing tropism calculated as Dnmt3a KO/wt ratio in the bone marrow, livers 
and spleens of recipient mice (n=4; ***, p<0.001). Dotted line represents ratio at time of 
injection (1.0).
C. Representative FACS plots showing distribution of fluorescently labeled WT and Dnmt3a 
KO cells homed to the indicated sites, gated on CD45+.
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D. Survival of lethally-irradiated recipient mice transplanted with total bone marrow from 
diseased Dnmt3a-null or control animals (n=10; ***, p=0.0003 by Gehan-Breslow-
Wilcoxon test).
E–F. Liver weights (E; n=5–7; ***, p<0.001) and H/E-stained sections (F) in primary 
recipients transplanted with Dnmt3a-ablated bone marrow cells at time of disease onset and 
in control wild-type mice. Arrows – megakaryocytes indicative of EMH.
G–H. Platelet (G) and monocyte (H) counts in the peripheral blood of mice transplanted 
with Dnmt3a-null bone marrow (n=8; ***, p<0.001).
I. Increased frequency of extramedullary hematopoiesis in CMML patients with DNMT3A 
mutations. Left panel represents observed frequencies of hepatosplenomegaly and 
lymphadenopathy in patients with different DNMT3A (wt or mutant) status (n=46); right 
panel shows expected frequencies for random distribution (p=0.053, Phi=+0.39, 2-tailed 
Fisher’s exact test).
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Figure 6. ERRBS DNA methylation and gene expression profiling identifies genomic features 
dysregulated by Dnmt3a loss
A. Dnmt3a-null LSK and GMP cells show overall methylation loss relative to wild-type in 
differentially methylated regions (DMRs).
B. CpGs contained in DMRs are enriched within introns, gene neighborhoods, and 
intergenic regions. CpGs with lower %methylation in Dnmt3a-null GMP cells compared to 
wild-type are defined as hypomethylated, and those with greater methylation in Dnmt3a-null 
GMP cells as hypermethylated (**, genomic compartments enriched for DMR-contained 
CpGs relative to other regions of the genome, Fisher’s exact test, one-tailed, p<0.01).
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C. Dnmt3a-null GMPs show methylation loss at GMP active enhancers relative to wild-type. 
GMP active enhancers ± 10kb were divided into 30 bins and the average methylation value 
in each was plotted.
D. Differential expression of genes covered by RNA-sequencing shows preferential 
upregulation of a subset of genes in Dnmt3a-null GMPs compared to wild-type controls. 
Dotted lines represent significance cutoffs set at ±1 Log(FC expression) (vertical) or −1 
Log(adjusted p-value) (horizontal).
E. List of gene ontology terms by DAVID functional annotation tool derived from DMCs 
mapping to gene promoters in GMP cells from Dnmt3a-null and control animals.
F. Heatmap of differentially expressed genes (adjusted p<0.1) based on RNA-sequencing of 
GMPs derived from Dnmt3a-null and wild-type control animals, z-score scale.
G. GSEA plots showing enrichment of the HSC gene signature36, modified fetal liver HSC 
signature37, and PRC2_EED_UP.V1_UP51, in Dnmt3a-null GMPs compared to wild-type 
controls.
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